Discontinuation of dolutegravir, elvitegravir/cobicistat and raltegravir because of toxicity in a prospective cohortJosep M. Llibre, Alexandra Montoliu, JM Miró et al.|HIV Medicine|2019Cited by 38
Strategies to reengage patients lost to follow up in HIV care in high income countries, a scoping reviewJorge Palacio‐Vieira, Eva González‐Roca, Juliana Reyes‐Urueña et al.|BMC Public Health|2021Cited by 37
Effectiveness and tolerability of dolutegravir/lamivudine for the treatment of HIV-1 infection in clinical practiceInés Suárez‐García, Julia Portilla, Cristina Moreno et al.|Journal of Antimicrobial Chemotherapy|2023Cited by 36
Maintenance therapy with dolutegravir and lamivudine versus bictegravir, emtricitabine, and tenofovir alafenamide in people with HIV (PASO-DOBLE): 48-week results from a randomised, multicentre, open-label, non-inferiority trialPablo Ryan, Estebán Martínez, José L Blanco et al.|The Lancet HIV|2025Cited by 22
Mortality and immunovirological outcomes in patients with advanced HIV disease on their first antiretroviral treatment: differential impact of antiretroviral regimensJoaquín Burgos, Jorge Palacio, Sergio Moreno‐Fornés et al.|Journal of Antimicrobial Chemotherapy|2022Cited by 22